These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 27272167)
1. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients? Desmaele S; Steurbaut S; Cornu P; Brouns R; Dupont AG Eur J Clin Pharmacol; 2016 Sep; 72(9):1125-34. PubMed ID: 27272167 [TBL] [Abstract][Full Text] [Related]
2. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Fanning L; Ilomäki J; Bell JS; Dārziņš P Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255 [TBL] [Abstract][Full Text] [Related]
3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420 [TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695 [TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067 [TBL] [Abstract][Full Text] [Related]
9. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
10. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494 [TBL] [Abstract][Full Text] [Related]
11. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255 [TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181 [TBL] [Abstract][Full Text] [Related]
14. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation. Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513 [TBL] [Abstract][Full Text] [Related]
16. Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study. Rottenkolber M; Schmiedl S; Ibánez L; Sabaté M; Ballarín E; Vidal X; Leon-Muñoz LM; Huerta C; Martin Merino E; Montero D; Gasse C; Andersen M; Aakjaer M; De Bruin ML; Gerlach R; Tauscher M; Souverein PC; van den Ham R; Klungel O; Gardarsdottir H; Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):440-454. PubMed ID: 33037766 [TBL] [Abstract][Full Text] [Related]
17. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
19. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. Oertel LB; Fogerty AE J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310 [TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]